Company

Neion Bio, Inc.

Neion Bio uses its Raptor platform to manufacture therapeutic proteins and other biological molecules.

About

Neion Bio develops biomanufacturing processes for monoclonal antibodies, enzymes, fusion proteins, peptides, and cytokines using its Raptor™ platform. It serves biopharmaceutical companies across North America, Europe, and parts of Asia. Founded in 2024 by Demetrios (Dimi) Kellari, Sam Levin, and Sven Bocklandt, the company is based in New York, US. In June 2026, it raised USD 23 million in Series A funding.

2Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in